Prognostic markers in prostate cancer.
In this review, a series of relatively well-documented ancillary biomarkers and emerging molecular assays are evaluated for their relative ability to predict prognosis in prostate cancer. Prognostic factors that have achieved widespread use and classified as Category I by the College of American Pathologists Solid Tumor Prognostic Factor Consensus Conference are compared with newer tests that are beginning to be used in clinical practice (Category II) and emerging molecular-based assays that have yet to be widely validated in the published literature or clinical trials (Category III).
Ross
Jeffrey S
JS
Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA. rossj@mail.amc.edu
Sheehan
Christine E
CE
Fisher
Hugh A G
HA
Kauffman
Ronald A
RA
Dolen
Eric M
EM
Kallakury
Bhaskar V S
BV
D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000032:analysis; D015815:Cell Adhesion Molecules / Q000032:analysis; D002453:Cell Cycle; D006133:Growth Substances / Q000032:analysis; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic; D009857:Oncogenes; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000098:blood supply / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology
D014408:Biomarkers, Tumor; D015815:Cell Adhesion Molecules; D006133:Growth Substances